Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1985 May;48(2):409–416. doi: 10.1128/iai.48.2.409-416.1985

Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

L E Adinolfi, P F Bonventre, M Vander Pas, D A Eppstein
PMCID: PMC261329  PMID: 3988341

Abstract

A regimen of immunostimulation with 6-0-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine, a lipophilic analog of muramyl dipeptide, combined with antimonial drug therapy was evaluated in the treatment of visceral leishmaniasis of mice and hamsters. The combined treatment was found to be more effective in the elimination of Leishmania donovani amastigotes from infected tissue macrophages than was either of the two treatments applied individually. In mice, it was found that immunostimulation of animals prophylactically, therapeutically, or both enhanced the effects of the antimonial drug (Glucantime) administered more than 1 week after a challenge of BALB/c and C57BL/6 mice. The superiority of the combined treatment of the parasite infection was demonstrable in both short-term (14 days) and long-term (40 to 45 days) infections of the two inbred strains of mice. The combined therapy was also effective in preventing the lethal course of leishmaniasis in hamsters which succumb to disseminated disease in the absence of therapeutic intervention. The efficacy of this dual approach to the therapy of disseminated leishmaniasis of experimental animals holds promise for similar application in the treatment of similarly afflicted human populations.

Full text

PDF
409

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agu W. E., Farrell J. P., Soulsby E. J. Pathogenesis of anaemia in hamsters infected with Leishmania donovani. Z Parasitenkd. 1982;68(1):27–32. doi: 10.1007/BF00926654. [DOI] [PubMed] [Google Scholar]
  2. Agu W. E., Farrell J. P., Soulsby E. J. Proliferative glomerulonephritis in experimental Leishmania donovani infection of the golden hamster. Comp Immunol Microbiol Infect Dis. 1981;4(3-4):353–368. doi: 10.1016/0147-9571(81)90021-7. [DOI] [PubMed] [Google Scholar]
  3. Blackwell J. M., Ulczak O. M. Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterization of suppressor T cells in noncure mice. Infect Immun. 1984 Apr;44(1):97–102. doi: 10.1128/iai.44.1.97-102.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bloom B. R. Games parasites play: how parasites evade immune surveillance. Nature. 1979 May 3;279(5708):21–26. doi: 10.1038/279021a0. [DOI] [PubMed] [Google Scholar]
  5. Carvalho E. M., Teixeira R. S., Johnson W. D., Jr Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun. 1981 Aug;33(2):498–500. doi: 10.1128/iai.33.2.498-500.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chedid L., Audibert F., Lefrancier P., Choay J., Lederer E. Modulation of the immune response by a synthetic adjuvant and analogs. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472–2475. doi: 10.1073/pnas.73.7.2472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cook J. A., Holbrook T. W., Parker B. W. Visceral leishmaniasis in mice: protective effect of glucan. J Reticuloendothel Soc. 1980 Jun;27(6):567–573. [PubMed] [Google Scholar]
  9. Cummings N. P., Pabst M. J., Johnston R. B., Jr Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J Exp Med. 1980 Dec 1;152(6):1659–1669. doi: 10.1084/jem.152.6.1659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Damais C., Parant M., Chedid L., Lefrancier P., Choay J. In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell Immunol. 1978 Jan;35(1):173–179. doi: 10.1016/0008-8749(78)90137-5. [DOI] [PubMed] [Google Scholar]
  11. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  12. Fevrier M., Birrien J. L., Leclerc C., Chedid L., Liacopoulos P. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur J Immunol. 1978 Aug;8(8):558–562. doi: 10.1002/eji.1830080804. [DOI] [PubMed] [Google Scholar]
  13. Fidler I. J., Sone S., Fogler W. E., Barnes Z. L. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1680–1684. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fidler I. J. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science. 1980 Jun 27;208(4451):1469–1471. doi: 10.1126/science.7384789. [DOI] [PubMed] [Google Scholar]
  15. Fiorilli M., Sirianni M. C., Pandolfi F., Quinti I., Tosti U., Aiuti F., Goldstein G. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency. Clin Exp Immunol. 1981 Aug;45(2):344–351. [PMC free article] [PubMed] [Google Scholar]
  16. Fraser-Smith E. B., Eppstein D. A., Larsen M. A., Matthews T. R. Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection. Infect Immun. 1983 Jan;39(1):172–178. doi: 10.1128/iai.39.1.172-178.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fraser-Smith E. B., Matthews T. R. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice. Infect Immun. 1981 Dec;34(3):676–683. doi: 10.1128/iai.34.3.676-683.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fraser-Smith E. B., Waters R. V., Matthews T. R. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Infect Immun. 1982 Jan;35(1):105–110. doi: 10.1128/iai.35.1.105-110.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Garnham P. C., Humphrey J. H. Problems in leishmaniasis related to immunology. Curr Top Microbiol Immunol. 1969;48:29–42. doi: 10.1007/978-3-642-46163-7_2. [DOI] [PubMed] [Google Scholar]
  20. Haidaris C. G., Bonventre P. F. Efficacy of combined immunostimulation and chemotherapy in experimental visceral Leishmaniasis. Am J Trop Med Hyg. 1983 Mar;32(2):286–295. doi: 10.4269/ajtmh.1983.32.286. [DOI] [PubMed] [Google Scholar]
  21. Haidaris C. G., Bonventre P. F. Elimination of Leishmania donovani amastigotes by activated macrophages. Infect Immun. 1981 Sep;33(3):918–926. doi: 10.1128/iai.33.3.918-926.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ho M., Koech D. K., Iha D. W., Bryceson A. D. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol. 1983 Feb;51(2):207–214. [PMC free article] [PubMed] [Google Scholar]
  23. Holbrook T. W., Cook J. A. Non-specific and specific stimulation of resistance against Leishmania donovani in C57BL/6 mice. Ann Clin Lab Sci. 1983 Sep-Oct;13(5):411–417. [PubMed] [Google Scholar]
  24. Kireszenbaum F., Ferraresi R. W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Krahenbuhl J. L., Sharma S. D., Ferraresi R. W., Remington J. S. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice. Infect Immun. 1981 Feb;31(2):716–722. doi: 10.1128/iai.31.2.716-722.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Leclerc C., Juy D., Bourgeois E., Chedid L. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol. 1979 Jun;45(1):199–206. doi: 10.1016/0008-8749(79)90377-0. [DOI] [PubMed] [Google Scholar]
  27. Leclerc C., Löwy I., Chedid L. Influence of MDP and of some analogous synthetic glycopeptides on the in vitro mouse spleen cell viability and immune response to sheep erythrocytes. Cell Immunol. 1978 Jul;38(2):286–293. doi: 10.1016/0008-8749(78)90059-x. [DOI] [PubMed] [Google Scholar]
  28. Lopez-Berestein G., Mehta K., Mehta R., Juliano R. L., Hersh E. M. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983 Apr;130(4):1500–1502. [PubMed] [Google Scholar]
  29. Lopez-Berestein G., Milas L., Hunter N., Mehta K., Hersh E. M., Kurahara C. G., Vandupas M., Eppstein D. A. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clin Exp Metastasis. 1984 Apr-Jun;2(2):127–137. doi: 10.1007/BF00052413. [DOI] [PubMed] [Google Scholar]
  30. Löwy I., Bona C., Chedid L. Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol. 1977 Mar 1;29(1):195–199. doi: 10.1016/0008-8749(77)90288-x. [DOI] [PubMed] [Google Scholar]
  31. Mehta K., Juliano R. L., Lopez-Berestein G. Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. Immunology. 1984 Mar;51(3):517–527. [PMC free article] [PubMed] [Google Scholar]
  32. Morozumi P. A., Brummer E., Stevens D. A. Immunostimulation with muramyl dipeptide and its desmethyl analogue: Studies of non-specific resistance to pulmonary blastomycosis in inbred mouse strains. Mycopathologia. 1983 Jan 17;81(1):35–39. doi: 10.1007/BF00443907. [DOI] [PubMed] [Google Scholar]
  33. North R. J. The concept of the activated macrophage. J Immunol. 1978 Sep;121(3):806–809. [PMC free article] [PubMed] [Google Scholar]
  34. Oppenheim J. J., Togawa A., Chedid L., Mizel S. Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol. 1980 Mar 1;50(1):71–81. doi: 10.1016/0008-8749(80)90007-6. [DOI] [PubMed] [Google Scholar]
  35. Parant M., Parant F., Chedid L., Yapo A., Petit J. F., Lederer E. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol. 1979;1(1):35–41. doi: 10.1016/0192-0561(79)90028-6. [DOI] [PubMed] [Google Scholar]
  36. Pearson R. D., Wheeler D. A., Harrison L. H., Kay H. D. The immunobiology of leishmaniasis. Rev Infect Dis. 1983 Sep-Oct;5(5):907–927. doi: 10.1093/clinids/5.5.907. [DOI] [PubMed] [Google Scholar]
  37. REISSIG J. L., STORMINGER J. L., LELOIR L. F. A modified colorimetric method for the estimation of N-acetylamino sugars. J Biol Chem. 1955 Dec;217(2):959–966. [PubMed] [Google Scholar]
  38. Reiner N. E., Finke J. H. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J Immunol. 1983 Sep;131(3):1487–1491. [PubMed] [Google Scholar]
  39. Skov C. B., Twohy D. W. Cellular immunity to Leishmania donovani. I. The effect of T cell depletion on resistance to L. donovani in mice. J Immunol. 1974 Dec;113(6):2004–2011. [PubMed] [Google Scholar]
  40. Smrkovski L. L., Larson C. L. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun. 1977 Apr;16(1):249–257. doi: 10.1128/iai.16.1.249-257.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Sone S., Fidler I. J. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol. 1981 Jan 1;57(1):42–50. doi: 10.1016/0008-8749(81)90118-0. [DOI] [PubMed] [Google Scholar]
  42. Sone S., Tsubura E. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol. 1982 Sep;129(3):1313–1317. [PubMed] [Google Scholar]
  43. Staruch M. J., Wood D. D. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo. J Immunol. 1982 Jan;128(1):155–160. [PubMed] [Google Scholar]
  44. Sugimura K., Uemiya M., Saiki I., Azuma I., Yamamura Y. The adjuvant activity of synthetic N-acetylmuramyl-dipeptide: evidence of initial target cells for the adjuvant activity. Cell Immunol. 1979 Mar 1;43(1):137–149. doi: 10.1016/0008-8749(79)90157-6. [DOI] [PubMed] [Google Scholar]
  45. Wahl S. M., Wahl L. M., McCarthy J. B., Chedid L., Mergenhagen S. E. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979 Jun;122(6):2226–2231. [PubMed] [Google Scholar]
  46. Waters R. V., Ferraresi R. W. Muramyl dipeptide stimulation of particle clearance in several animal species. J Reticuloendothel Soc. 1980 Nov;28(5):457–471. [PubMed] [Google Scholar]
  47. Wood D. D., Staruch M. J. Control of the mitogenicity of muramyl dipeptide. Int J Immunopharmacol. 1981;3(1):31–44. doi: 10.1016/0192-0561(81)90043-6. [DOI] [PubMed] [Google Scholar]
  48. Yamamoto Y., Nagao S., Tanaka A., Koga T., Onoue K. Inhibition of macrophage migration by synthetic muramyl dipeptide. Biochem Biophys Res Commun. 1978 Feb 28;80(4):923–928. doi: 10.1016/0006-291x(78)91333-5. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES